What is Black Diamond Therapeutics Inc?
, a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 75.28M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.